According to SPER Market Research, the Cell & Gene Therapy Manufacturing Services Market is cell treatment and gene therapy. Cell therapy aims to heal illnesses and diseases by regenerating or changing certain cell types, or by supplying cells to deliver medicine throughout the body. The patient’s cells are initially produced or modified outside of the body while using cell therapy. The patient’s own cells (autologous cells) or those from a donor may be used (allogeneic cells). In order to treat disorders, gene therapy either replaces or introduces genes into cells in vivo (inside the body) or ex vivo (outside the body) (ex vivo). In addition to rising R&D spending by pharmaceutical companies, the market is growing as a result of rising rates of cancer and other target diseases.
During the Covid-19 pandemic, the market for manufacturing services for cell and gene therapies declined due to the limitations on running capacity imposed by the government and the disruption of the supply chain and logistical infrastructure. This has led to an increase in demand for these services, which is projected to have a significant impact on market growth. Additionally, BioCardia’s application for an Investigational New Drug (IND) to start a Phase I/II clinical trial of COVID-19 stem cell therapy was authorised by the US Food and Drug Administration (FDA). This will result in an increase in the use of contract manufacturing services.
- Forecast CAGR (2022-2032): 17.74%.
- Forecast Market Size (2032): 26.11 billion.
Impact of COVID-19 on the Global Cell & Gene Therapy Manufacturing Services Market:
The market for manufacturing services for cell and gene therapies suffered during the COVID-19 pandemic. The government-imposed running capacity restrictions and the disruption of the supply chain and logistical systems were the two main causes of this. The United States Food and Drug Administration’s Coronavirus Treatment Acceleration Program (CTAP) 2020 states that COVID-19-related therapies include cell therapy products, such as cellular immunotherapies and other kinds of autologous and allogeneic cells, like stem cells, and associated goods. As a result, the need for manufacturing services rises as a result of the treatment of COVID-19 with cell therapy products, which is anticipated to have a major impact on market growth. Additionally, the US Food and Drug Administration (FDA) authorised BioCardia to begin a Phase I/II clinical trial of COVID-19 stem cell therapy, BCDA-04, in adults recovering from COVID-19-related acute respiratory distress syndrome (ARDS). These new IND applications for treating COVID-19 will encourage more businesses to use contract manufacturing services.
Request For Free sample report @ https://www.sperresearch.com/report-store/cell-and-gene-therapy-manufacturing-services-market.aspx?sample=1
Cell & Gene Therapy Manufacturing Services Market Key Segments Covered:
The SPER Market Research report seeks to give market dynamics, demand, and supply forecasts for the years up to 2032. This report contains statistics on product type segment growth estimates and forecasts.
By Therapy Type:
- Cell Therapy Manufacturing
- Gene Therapy Manufacturing
- Pre-commercial/ R&D Manufacturing
- Commercial Scale Manufacturing
- Contract Manufacturing
- In-house Manufacturing
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical And Quality Testing
- Middle East
- North America
- Latin America
Based on geography, The Global Cell & Gene Therapy Manufacturing Services Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Due to the ongoing advancements in the regional industry, the Asia Pacific market is anticipated to present a sizable potential to the market.
Cell & Gene Therapy Manufacturing Services Market Key Players:
The market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as; Bluebird Bio Inc., Boehringer Ingelheim, Catalent Inc., Cellular Therapeutics, F. Hoffmann-La Roche Ltd, Hitachi Chemical Co. Ltd., Lonza, Merck KGaA, Miltenyi Biotec, Novartis AG, Samsung Biologics, Takara Bio Inc., Thermo Fisher Scientific, Wuxi Advanced Therapies.
For More Information, refer to below link: –
Follow Us –
Sara Lopes, Business Consultant – USA
SPER Market Research